CL2024001372A1 - Conjugados que comprenden fósforo (v) y una fracción molecular de droga - Google Patents
Conjugados que comprenden fósforo (v) y una fracción molecular de drogaInfo
- Publication number
- CL2024001372A1 CL2024001372A1 CL2024001372A CL2024001372A CL2024001372A1 CL 2024001372 A1 CL2024001372 A1 CL 2024001372A1 CL 2024001372 A CL2024001372 A CL 2024001372A CL 2024001372 A CL2024001372 A CL 2024001372A CL 2024001372 A1 CL2024001372 A1 CL 2024001372A1
- Authority
- CL
- Chile
- Prior art keywords
- conjugates
- phosphorus
- molecular moiety
- drug molecular
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4476—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21207195 | 2021-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001372A1 true CL2024001372A1 (es) | 2024-10-25 |
Family
ID=78592631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001372A CL2024001372A1 (es) | 2021-11-09 | 2024-05-06 | Conjugados que comprenden fósforo (v) y una fracción molecular de droga |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230330258A1 (https=) |
| EP (1) | EP4429708A1 (https=) |
| JP (1) | JP2024540691A (https=) |
| KR (1) | KR20240100413A (https=) |
| CN (1) | CN118302197A (https=) |
| AU (1) | AU2022385379A1 (https=) |
| CA (1) | CA3237371A1 (https=) |
| CL (1) | CL2024001372A1 (https=) |
| CO (1) | CO2024005877A2 (https=) |
| DE (1) | DE22817174T1 (https=) |
| ES (1) | ES2999335T1 (https=) |
| IL (1) | IL312675A (https=) |
| MX (1) | MX2024005546A (https=) |
| PE (1) | PE20242107A1 (https=) |
| WO (1) | WO2023083900A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024133845A1 (en) * | 2022-12-22 | 2024-06-27 | Tubulis Gmbh | Conjugates comprising a phosphorus(v) moiety and a drug |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| WO2025046090A1 (en) | 2023-09-01 | 2025-03-06 | Tubulis Gmbh | Methods of preparing phosphonamidate compounds |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| EP4658320A1 (en) | 2024-02-27 | 2025-12-10 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025262641A1 (en) | 2024-06-19 | 2025-12-26 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633410A (en) | 1898-09-22 | 1899-09-19 | George A Ames | Ice-cutter. |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| JP2763020B2 (ja) | 1995-04-27 | 1998-06-11 | 日本電気株式会社 | 半導体パッケージ及び半導体装置 |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| EP1731174A3 (en) | 1996-08-02 | 2007-01-17 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| KR20200058590A (ko) | 2008-04-30 | 2020-05-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| ES2826398T3 (es) | 2013-10-15 | 2021-05-18 | Seagen Inc | Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco |
| AU2017320913B2 (en) | 2016-09-01 | 2024-08-15 | Forschungsverbund Berlin E.V. | Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates |
| JP7429191B2 (ja) | 2018-03-07 | 2024-02-07 | フォルシュングスフェアバント ベルリン エー．ベー． | アルケンホスホノチオレートまたはアルキンホスホノチオレートおよびアルケンホスホネートまたはアルキンホスホネートとの化学選択的チオールコンジュゲーション |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
-
2022
- 2022-11-09 CN CN202280074835.4A patent/CN118302197A/zh active Pending
- 2022-11-09 CA CA3237371A patent/CA3237371A1/en active Pending
- 2022-11-09 PE PE2024001005A patent/PE20242107A1/es unknown
- 2022-11-09 IL IL312675A patent/IL312675A/en unknown
- 2022-11-09 MX MX2024005546A patent/MX2024005546A/es unknown
- 2022-11-09 DE DE22817174.0T patent/DE22817174T1/de active Pending
- 2022-11-09 WO PCT/EP2022/081345 patent/WO2023083900A1/en not_active Ceased
- 2022-11-09 US US18/054,018 patent/US20230330258A1/en not_active Abandoned
- 2022-11-09 KR KR1020247019065A patent/KR20240100413A/ko active Pending
- 2022-11-09 EP EP22817174.0A patent/EP4429708A1/en active Pending
- 2022-11-09 AU AU2022385379A patent/AU2022385379A1/en active Pending
- 2022-11-09 JP JP2024549576A patent/JP2024540691A/ja active Pending
- 2022-11-09 ES ES22817174T patent/ES2999335T1/es active Pending
-
2024
- 2024-05-06 CO CONC2024/0005877A patent/CO2024005877A2/es unknown
- 2024-05-06 CL CL2024001372A patent/CL2024001372A1/es unknown
-
2025
- 2025-05-14 US US19/207,970 patent/US20250281634A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20242107A1 (es) | 2024-10-28 |
| CA3237371A1 (en) | 2023-05-19 |
| AU2022385379A1 (en) | 2024-06-20 |
| WO2023083900A1 (en) | 2023-05-19 |
| MX2024005546A (es) | 2024-07-10 |
| CO2024005877A2 (es) | 2024-07-08 |
| EP4429708A1 (en) | 2024-09-18 |
| US20230330258A1 (en) | 2023-10-19 |
| ES2999335T1 (en) | 2025-02-25 |
| KR20240100413A (ko) | 2024-07-01 |
| US20250281634A1 (en) | 2025-09-11 |
| CN118302197A (zh) | 2024-07-05 |
| IL312675A (en) | 2024-07-01 |
| JP2024540691A (ja) | 2024-10-31 |
| DE22817174T1 (de) | 2024-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001372A1 (es) | Conjugados que comprenden fósforo (v) y una fracción molecular de droga | |
| CL2024001373A1 (es) | Conjugados que comprenden fósforo (v) y una fracción molecular de camptotecina | |
| EA201992081A1 (ru) | Конъюгирование цитотоксических лекарственных средств посредством бис-связывания | |
| CL2021000901A1 (es) | Enlazadores de conjugación que contienen el grupo 2,3-diaminosuccinilo | |
| BRPI0910388A2 (pt) | agentes terapêutico antivirais. | |
| CY1112278T1 (el) | Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους | |
| BR112013023015A8 (pt) | conjugado de amatoxina e seu uso, composição farmacêutica e seu uso, molécula de conjugação de amatoxina, método para a síntese de um conjungado de amatoxina. | |
| BR112016002829A2 (pt) | Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi | |
| CO2024006160A2 (es) | Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este | |
| BRPI0611872B8 (pt) | reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica | |
| EA200800657A1 (ru) | Способ приготовления очищенных конъюгатов лекарственных средств | |
| BR112016004023A2 (pt) | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto | |
| MX2021004884A (es) | Conjugado anticuerpo anti-factor de crecimiento epidermico humano 3 (anti-her3-farmaco). | |
| MX2019001093A (es) | Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos. | |
| MX2020009971A (es) | Conjugado anticuerpo anti-trop2-farmaco. | |
| MX368966B (es) | Conjugados de proteina-polimero-farmaco. | |
| NI201200012A (es) | Profármacos que comprenden un conjugado de insulina - conector | |
| CY1113258T1 (el) | Συμπλοκο φυλλικου- βινβλαστινης ως φαρμακο | |
| ECSP11010804A (es) | Compuestos orgánicos | |
| BR112022002309A2 (pt) | Conjugado e usos do mesmo | |
| CY1122416T1 (el) | Φαρμακα τα οποια περιεχουν κρυσταλλικες τροποποιησεις (1r,2r)-3-(3-δimeθyλamino-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης | |
| MX2010005813A (es) | Conjugados oligomero-triciclicos. | |
| MX2018009585A (es) | Conjugados de pirrolobenzodiazepina. | |
| BRPI0607309A2 (pt) | processos para a preparação de fenilpirazol uréias substituìdas | |
| UY29639A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos |